New mapping technique may improve heart rhythm procedure

NCT ID NCT03915691

Ongoing Disease control Sponsor: Liverpool Heart and Chest Hospital NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests two ways to do a catheter ablation for a type of fast heartbeat called atrial tachycardia that comes from heart scar tissue. One method uses a new mapping system (Ripple Mapping) to guide the ablation, while the other uses the standard approach. The goal is to see which method better prevents the arrhythmia from coming back within a year. About 200 adults who need this procedure are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Catheter ablation (Ripple Mapping guided or conventional mapping guided)
What this could lead to: If successful, this could identify a more effective ablation technique to reduce the return of atrial tachycardia after the procedure.
What could go wrong: This is a mid-stage study with no phase designation, and the outcome depends on long-term follow-up. The procedure itself carries standard risks like bleeding or heart damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL TACHYCARDIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL TACHYCARDIA

Contacts and locations

Locations

Freeman Hospital, The Newcastle Upon Tyne NHS Foundation Trust

Newcastle, NE7 7DN, United Kingdom
Imperial College Healthcare NHS Trust

London, W12 0HS, United Kingdom
Liverpool Heart & Chest Hospital

London, L14 3PE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.